Question 1

Am I eligible for this trial based on my current health and treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant clinical trial (NCT04530630). Contact the study team or your healthcare provider for specific answers.

Question 2

How does BIC/F/TAF compare to my current HIV treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant clinical trial (NCT04530630). Contact the study team or your healthcare provider for specific answers.

Question 3

What potential side effects should I be aware of with this new medication?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant clinical trial (NCT04530630). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my health be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant clinical trial (NCT04530630). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects while participating?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant clinical trial (NCT04530630). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any travel or logistical considerations I should know about if I join this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant clinical trial (NCT04530630). Contact the study team or your healthcare provider for specific answers.

What this study is about